Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Equity Average (2019 - 2025)

Historic Equity Average for Exagen (XGN) over the last 7 years, with Q3 2025 value amounting to $19.6 million.

  • Exagen's Equity Average rose 2863.1% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 2863.1%. This contributed to the annual value of $16.1 million for FY2024, which is 5052.64% down from last year.
  • Latest data reveals that Exagen reported Equity Average of $19.6 million as of Q3 2025, which was up 2863.1% from $13.7 million recorded in Q2 2025.
  • Exagen's 5-year Equity Average high stood at $98.9 million for Q2 2021, and its period low was $8.0 million during Q1 2025.
  • Moreover, its 5-year median value for Equity Average was $33.9 million (2023), whereas its average is $44.6 million.
  • Per our database at Business Quant, Exagen's Equity Average soared by 10360.66% in 2021 and then tumbled by 6264.96% in 2025.
  • Exagen's Equity Average (Quarter) stood at $87.9 million in 2021, then tumbled by 43.87% to $49.3 million in 2022, then plummeted by 49.11% to $25.1 million in 2023, then tumbled by 55.36% to $11.2 million in 2024, then soared by 74.81% to $19.6 million in 2025.
  • Its Equity Average stands at $19.6 million for Q3 2025, versus $13.7 million for Q2 2025 and $8.0 million for Q1 2025.